CollPlant Biotechnologies Ltd

CollPlant Holdings Ltd. is a regenerative and aesthetic medicine company that develops dermal and soft tissue fillers and bioprinting products using its proprietary recombinant human type I collagen platform extracted from tobacco plants. Its core commercialized products include VergenixFG and VergenixSTR, aesthetic fillers for physicians and patients, while it also produces bioinks for tissue engineering applications and operates clinical-stage candidates through a strategic partnership with AbbVie for combined product development in medical aesthetics. The company generates revenue from product sales, technology licensing, and development milestone payments from partners, targeting physicians, patients, and medical device companies in the medical aesthetics and regenerative medicine markets, either through independent commercialization or collaborative arrangements.